SPOTLIGHT -
Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
Outlook Therapeutics submits UK Marketing Authorization Application for wet AMD treatment
I-SCREEN project set to use AI for AMD diagnosis across Europe
India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD
EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901
John Han, PharmD named Vice President, Medical Affairs for Opthea Limited
Clinical trials: Companies tackle AMD in early 2024